Literature DB >> 34093104

Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications.

Mehdi Azizi1, Hassan Dianat-Moghadam2, Roya Salehi3, Masoud Farshbaf4, Disha Iyengar5, Samaresh Sau5, Arun K Iyer5, Hadi Valizadeh3, Mohammad Mehrmohammadi6, Michael R Hamblin7.   

Abstract

Although considerable efforts have been conducted to diagnose, improve, and treat cancer in the past few decades, existing therapeutic options are insufficient, as mortality and morbidity rates remain high. Perhaps the best hope for substantial improvement lies in early detection. Recent advances in nanotechnology are expected to increase the current understanding of tumor biology, and will allow nanomaterials to be used for targeting and imaging both in vitro and in vivo experimental models. Owing to their intrinsic physicochemical characteristics, nanostructures (NSs) are valuable tools that have received much attention in nanoimaging. Consequently, rationally designed NSs have been successfully employed in cancer imaging for targeting cancer-specific or cancer-associated molecules and pathways. This review categorizes imaging and targeting approaches according to cancer type, and also highlights some new safe approaches involving membrane-coated nanoparticles, tumor cell-derived extracellular vesicles, circulating tumor cells, cell-free DNAs, and cancer stem cells in the hope of developing more precise targeting and multifunctional nanotechnology-based imaging probes in the future.

Entities:  

Keywords:  active targeting; nanotechnology-based imaging; passive targeting; targeted nanoplatforms; tumor biology

Year:  2020        PMID: 34093104      PMCID: PMC8174103          DOI: 10.1002/adfm.201910402

Source DB:  PubMed          Journal:  Adv Funct Mater        ISSN: 1616-301X            Impact factor:   18.808


  328 in total

1.  αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Authors:  Anna Sophie Berghoff; Astrid Kerstin Kovanda; Thomas Melchardt; Rupert Bartsch; Johannes A Hainfellner; Bence Sipos; Jens Schittenhelm; Christoph C Zielinski; Georg Widhalm; Karin Dieckmann; Michael Weller; Simon L Goodman; Peter Birner; Matthias Preusser
Journal:  Clin Exp Metastasis       Date:  2014-08-24       Impact factor: 5.150

2.  Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model.

Authors:  Amelie M Lutz; Sunitha V Bachawal; Charles W Drescher; Marybeth A Pysz; Jürgen K Willmann; Sanjiv Sam Gambhir
Journal:  Clin Cancer Res       Date:  2014-01-03       Impact factor: 12.531

3.  Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.

Authors:  Miriam Benezra; Oula Penate-Medina; Pat B Zanzonico; David Schaer; Hooisweng Ow; Andrew Burns; Elisa DeStanchina; Valerie Longo; Erik Herz; Srikant Iyer; Jedd Wolchok; Steven M Larson; Ulrich Wiesner; Michelle S Bradbury
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

Review 4.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

5.  Simultaneous fluorescence sensing of Cys and GSH from different emission channels.

Authors:  Jing Liu; Yuan-Qiang Sun; Yingying Huo; Hongxing Zhang; Linfang Wang; Pei Zhang; Dan Song; Yawei Shi; Wei Guo
Journal:  J Am Chem Soc       Date:  2013-12-30       Impact factor: 15.419

6.  ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.

Authors:  Christopher G England; Dawei Jiang; Reinier Hernandez; Haiyan Sun; Hector F Valdovinos; Emily B Ehlerding; Jonathan W Engle; Yunan Yang; Peng Huang; Weibo Cai
Journal:  Mol Pharm       Date:  2017-09-06       Impact factor: 4.939

7.  Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location.

Authors:  Jillian L Perry; Kevin G Reuter; J Christopher Luft; Chad V Pecot; William Zamboni; Joseph M DeSimone
Journal:  Nano Lett       Date:  2017-04-11       Impact factor: 11.189

Review 8.  Molecular pathways and therapeutic targets in lung cancer.

Authors:  Emma Shtivelman; Thomas Hensing; George R Simon; Phillip A Dennis; Gregory A Otterson; Raphael Bueno; Ravi Salgia
Journal:  Oncotarget       Date:  2014-03-30

9.  Macrophage membrane-coated iron oxide nanoparticles for enhanced photothermal tumor therapy.

Authors:  Qian-Fang Meng; Lang Rao; Minghui Zan; Ming Chen; Guang-Tao Yu; Xiaoyun Wei; Zhuhao Wu; Yue Sun; Shi-Shang Guo; Xing-Zhong Zhao; Fu-Bing Wang; Wei Liu
Journal:  Nanotechnology       Date:  2018-04-03       Impact factor: 3.874

10.  Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft.

Authors:  Shuanglong Liu; Dan Li; Jiacong Guo; Nicolette Canale; Xiuqing Li; Ren Liu; Valery Krasnoperov; Parkash S Gill; Peter S Conti; Hong Shan; Zibo Li
Journal:  Mol Pharm       Date:  2014-07-09       Impact factor: 4.939

View more
  4 in total

1.  Analysis on the Effects of CT- and Ultrasound-Guided Percutaneous Transthoracic Needle Biopsy Combined with Serum CA125 and CEA on the Diagnosis of Lung Cancer.

Authors:  Zhaoyin Wang; Jinbiao Huang; Minke Wang; Weixu Bi; Tianbing Fan
Journal:  J Healthc Eng       Date:  2022-01-07       Impact factor: 2.682

Review 2.  Quantifying and controlling bond multivalency for advanced nanoparticle targeting to cells.

Authors:  Elliot Y Makhani; Ailin Zhang; Jered B Haun
Journal:  Nano Converg       Date:  2021-11-30

3.  Decylubiquinone Inhibits Colorectal Cancer Growth Through Upregulating Sirtuin2.

Authors:  Jinlian Li; Shuting Zheng; Ting Cheng; Yuanyuan Li; Xiaobin Mai; Guangchun Jiang; Yongxia Yang; Qianqian Zhang; Jiangchao Li; Lingyun Zheng; Lijing Wang; Cuiling Qi
Journal:  Front Pharmacol       Date:  2022-02-01       Impact factor: 5.810

Review 4.  Nanoengineering facilitating the target mission: targeted extracellular vesicles delivery systems design.

Authors:  Haoyue Song; Xiaohang Chen; Yujia Hao; Jia Wang; Qingpeng Xie; Xing Wang
Journal:  J Nanobiotechnology       Date:  2022-09-29       Impact factor: 9.429

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.